Dealing with the Monkeypox crisis: Bavarian Nordic wins FDA approval to supply its vaccine

Dealing with the Monkeypox crisis: Bavarian Nordic wins FDA approval to supply its vaccine

The World Health Organization declared Monkeypox a global health emergency on July 23, around the same time as the number of confirmed cases reported in the United States reached 3,500—the second highest in the world.

So it is good timing for the Danish company Bavarian Nordic that their Jynneos smallpox vaccine, a suitable treatment for the disease, has won approval from the US Food and Drug Administration (FDA) and the European Medicines Agency.

Close to a million doses
The approval will help the FDA with its pledge Wednesday to provide 786,000 additional doses of monkeypox vaccine to local health departments “as soon as possible.”

“We are grateful to both the FDA and the EMA for expediting their review, and we look forward to continuing our work with health authorities around the globe to ensure the supply of vaccines against Monkeypox,” noted Bavarian Nordic CEO Paul Chaplin.

Men more likely to get it
The monkeypox virus has now broken out in 76 countries worldwide.

Men are more susceptible than women to getting the disease and so far account for over 90 percent of all cases.

Source: The Nordic Page

Related Posts: